Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Weighs Patients' Risk Tolerance in Approving Obesity Device

This article was originally published in The Gray Sheet

Executive Summary

The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.

Advertisement

Related Content

Final Guidance Encourages Use Of Patient Preference In Device Applications
Assistive, Neurostim Devices Get 'Patient Preference' Attention From US FDA
CDRH Prioritizes Leveraging Real-World And Patient-Preference Data, Enhancing Quality
People Briefs
FDA Launches Patient Engagement Advisory Committee For Devices
People Briefs: EnteroMedics, Direct Flow Medical, Veracyte, VolitionRx, Nuvasive
FDA Validates Tool For Incorporating Patient Preferences In Regulatory Decisions
FDA Takes Initial Steps To Quantify Patient Opinion
FDA Proposes Sliding-Scale Paradigm For Obesity Device Trials
Underpenetrated U.S. Gastric Banding Market Has Room For Two

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT034059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel